Since launch, over 20,500 patients have had RAYALDEE prescribed by nearly 3,200 physicians. Approximately 200 physicians or about 6% of the total number of prescribers were new RAYALDEE prescribers in Q2. Our partner, Vifor Fresenius, expect to soon receive on a decentralized marketing authorization application, European approvals for RAYALDEE in all countries in which the application was filed, and to launch the product as soon as possible thereafter.